OT mobile menu

Search form


ASH 2016

58th Annual ASH Meeting

OncoTherapy Network presents exclusive coverage from the 58th Annual American Society of Hematology (ASH) Meeting & Exposition, held December 3–6 in San Diego, California. We bring you interviews with experts in the field and on-site reports as we cover the latest research, trials, and scientific advances changing the way hematologic malignancies are managed and treated.

ASH 2016

For the first time, a study shows that using an immunomodulatory agent as maintenance therapy prolongs progression-free survival for patients with diffuse large B-cell lymphoma after first-line treatment with rituximab plus CHOP.

A study of pediatric acute lymphoblastic leukemia (ALL) has identified IKZF1 as a new ALL predisposition gene that may play a role both in leukemia pathogenesis and treatment responsiveness.

Ibrutinib can be safely combined with lenalidomide and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma, according to a new study presented at the American Society of Hematology 58th Annual Meeting and Exposition, held December 3–6.

We are speaking with Sonali Smith, MD, an associate professor of medicine and the director of the lymphoma program at the University of Chicago. At the ASH meeting, Dr. Smith will give a talk called “Emerging Biology Leading to New Therapies in Follicular Lymphoma.”

Researchers reporting at the American Society of Hematology annual meeting this week say there is a link between a treatment for autoimmune disease and the development of leukemia.

Brentuximab vedotin (BV) induces significantly superior clinical outcomes in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL) as compared with physician's choice with methotrexate or bexarotene, according to a new study presented at the American Society of Hematology Annual Meeting & Exposition, held December 3–6, 2016.

Obinutuzumab-based therapy is superior to rituximab-based therapy in patients with previously untreated advanced follicular lymphoma.


Subscribe to ASH 2016 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.